[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].


BACKGROUND Telaprevir, sale of which was suspended, has been approved in combination with pegylated interferon and ribavirin (triple therapy) in the treatment of chronic hepatitis C virus (HCV). Skin eruptions and isolated cases of severe cutaneous adverse reactions (SCAR) have been reported. AIMS Our aim was to assess the incidence of skin eruption and… (More)
DOI: 10.1016/j.annder.2016.02.028

1 Figure or Table


  • Presentations referencing similar topics